Abstract 280P
Background
HER2DX test is a genomic assay that evaluates the expression of 27 genes across four signatures (proliferation, luminal, immune and HER2 amplicon). The test provides prognostic (HER2DX risk score), predictive (HER2DX pathological complete response (pCR) score) information and levels of ERBB2 expression (ERBB2-score) in HER2+ early breast cancer (BC). We outline the preliminary results from the ongoing decision impact study of HER2DX at Valencia.
Methods
We conducted an observational, prospective, pilot, multicentric study involving 10 hospitals since Feb-23 (ongoing) to evaluate the clinical utility of HER2DX in early-stage HER2+ BC patients (pts). The main objective was to assess the % of change in the therapeutic plan after obtaining the HER2DX report.
Results
We analyzed the first consecutive 66 HER2DX tests performed. Median age was 54 years (range 28-79). The majority of pts were classified as stage II (66.7%), follow by stage I (19.7%), and stage III (13.6%). Luminal-HER2+ represented 66.7% of cases, and median ki67 was 30% (range 10-95%). Notably, 15.2% of test were conducted post-surgery. Among stage II, 50% of pts presented a high relapse risk, while, only 23.1% of stage I and 88.9% of stage III were considered high risk. A change in the treatment plan before and after the HER2DX result was observed in 27 of 66 (40.9%) cases, with 67.9% of the cases involving pts diagnosed at stage II. De-escalation of therapy was observed in 92.3% of pts (less poly-chemotherapy).
Conclusions
Our findings demonstrate the significant impact of HER2DX on clinical management decisions in early HER2+ BC, prompting oncologist to modify treatment strategies based on its results.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
364P - Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase Ib/II study
Presenter: Eva Ciruelos
Session: Poster session 14
365P - Interim analysis (IA) of the giredestrant (G) + samuraciclib (SAMURA) arm in MORPHEUS breast cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)
Presenter: Mafalda Oliveira
Session: Poster session 14
366P - Exploring the benefit of combining paclitaxel with capivasertib treatment in PI3K/AKT/PTEN-altered and non-altered TNBC preclinical models
Presenter: Cath Eberlein
Session: Poster session 14
367P - Phase I/II dose escalation study evaluating first-in-class eIF4A inhibitor zotatifin in ER+ metastatic breast cancer
Presenter: Ezra Rosen
Session: Poster session 14
368P - Tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR+/HER2- advanced breast cancer after CDK4/6 inhibitors: Preliminary findings of a multi-center, phase II study
Presenter: Qiufan Zheng
Session: Poster session 14
370P - A phase Ib study to evaluate the efficacy and safety of afuresertib plus fulvestrant in subjects with locally advanced or metastatic HR+/HER2- breast cancer who failed standard of care therapies: A subgroup analysis of efficacy in PIK3CA/AKT1/PTEN-altered subjects
Presenter: Pin Zhang
Session: Poster session 14
371P - Efficacy of metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer: The phase III MECCA trial
Presenter: Shusen Wang
Session: Poster session 14